Leman Biotech (莱芒生物)

Shen Zhen Shi, China

Biotech Therapeutics Cancer Care Drug Development

Leman (莱芒生物) was co-founded by Professor Tang Li's team at the Swiss Federal Institute of Technology in Lausanne (EPFL) and Jingtai Technology. It is an innovative tumor immunotherapy drug research and development company based on immune metabolic reprogramming (Meta 10) + cutting-edge artificial intelligence (AI), focusing on the research, development, production and commercialization of new tumor immunotherapy drugs. The core technology Meta 10 has shown great potential for curing solid tumors. The relevant results have been published in the top international academic journal Nature Immunology, and PCT patents have been applied for (entering 56 countries or regions, covering major economies in the world).

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Leman Biotech (莱芒生物) on @MedStartr Today #SolidTumors #Biotech #Therapeutics #CancerCare #DrugDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/CB8GqLVOGWw

Get Involved in Leman Biotech (莱芒生物)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2021
Website: www.lemanbio.com/

Disease Areas

Solid Tumors

Technologies

BiotherapeuticsOncology

🌐Website

What do you think of Leman Biotech (莱芒生物)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.